Chimeric Antigen Receptors to CD22 for Treating Hematological Cancers

Technology Bundle IDNCI-E-291-2012 Chimeric Antigen Receptors to CD22 for Treating Hematological CancersApplicationsTherapeuticsLead InventorsIra Pastan (NCI)Co-InventorsCrystal Mackall (NCI)Dimiter Dimitrov (NCI)Rimas Orentas (NCI)Development StatusClinicalICsNCIChimeric antigen receptors (CARs) are hybrid proteins consisting of an antibody binding fragment fused to protein signaling domains that cause T-cells which express the CAR to become cytotoxic.   Once activated, these cytotoxic T-cells can selectively eliminate the cells which they recognize via the antibody binding fragment of the CAR.  Thus, by engineering a T-cell to express a CAR that is specific for a certain cell surface protein, it is possible to selectively target those cells for destruction.  This promising new therapeutic approach is known as adoptive cell therapy.  CD22 is a cell surface protein expressed on a large number of B-cell lineage hematological cancers, such as leukemia and lymphoma.   Several promising therapies are being developed which target CD22, including therapeutic antibodies and immunotoxins.  This technology concerns the use of a high affinity antibody binding fragment to CD22 (known as m971), as the targeting moiety of a CAR. The resulting CAR can be used in adoptiv e cell therapy treatment for cancer.Commercial ApplicationsTreatment of diseases associated with increased or preferential expression of CD22Hematological cancers such as chronic lymphocytic leukemia (CLL), hairy ce...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research